Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05155254
Title IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors IO Biotech
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS


No variant requirements are available.